Alector Inc [ALEC] stock prices are up 8.18% to $7.01 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALEC shares have gain 10.57% over the last week, with a monthly amount glided 16.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023.
From an analyst’s perspective:
Alector Inc [NASDAQ: ALEC] stock has seen the most recent analyst activity on December 14, 2023, when Stifel upgraded its rating to a Buy and also boosted its price target to $15 from $8. Previously, Deutsche Bank started tracking the stock with Buy rating on December 12, 2023, and set its price target to $12. On September 25, 2023, Goldman initiated with a Sell rating and assigned a price target of $4 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $13 on September 22, 2023. BofA Securities downgraded its rating to a Neutral and reduced its price target to $12 on January 06, 2023. Morgan Stanley downgraded its rating to Equal-Weight for this stock on September 09, 2022, and downed its price target to $13. In a note dated July 07, 2022, Mizuho initiated an Buy rating and provided a target price of $15 on this stock.
The stock price of Alector Inc [ALEC] has been fluctuating between $3.66 and $9.13 over the past year. Alector Inc [NASDAQ: ALEC] shares were valued at $7.01 at the most recent close of the market.
Analyzing the ALEC fundamentals
The Alector Inc [NASDAQ:ALEC] reported sales of 96.31M for trailing twelve months, representing a drop of -38.67%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.65 points at the first support level, and at 6.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.22, and for the 2nd resistance point, it is at 7.42.
Alector Inc [ALEC] reported earnings per share of -$0.53 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.66/share, meaning a difference of $0.13 and a surprise factor of 19.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.02 per share as compared to estimates of -$0.82 per share, a difference of $0.84 representing a surprise of 102.40%.
Ratios To Look Out For
It’s worth pointing out that Alector Inc [NASDAQ:ALEC]’s Current Ratio is 3.95. In addition, the Quick Ratio stands at 3.95 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 6.92, the price to book ratio is 3.63.
Transactions by insiders
Recent insider trading involved Rosenthal Arnon, Chief Executive Officer, that happened on Dec 04 when 23831.0 shares were sold. President and Head of R&D, Kenkare-Mitra Sara completed a deal on Dec 04 to sell 12519.0 shares. Meanwhile, Chief Medical Officer Romano Gary sold 5035.0 shares on Dec 04.
